Global Local Anesthesia Drugs Market Research Report 2020 (Includes Business Impact of COVID-19)

  • TBI714638
  • October 15, 2020
  • Global
  • 92 pages
  • QY Market Research
                                          

Local anesthetics are commonly used in the department of stomatology, ophthalmology, gynecology and some minor surgeries to temporarily relieve pain. The fundamental difference between local anesthesia and general anaesthesia lies in that after the combination of local anesthesia with some specific parts of the sodium ion channel on the nerve membrane, the sodium ion in the sodium ion channel decreases so as to change the nerve membrane potential, causing the conduction of nerve impulse to be blocked, and finally realize the anesthetic effect. General anesthesia, on the other hand, works by affecting the physical properties of the membrane, such as the fluid and permeability of the membrane. As the number of surgeries increases, the need for postoperative pain relief programs increases significantly. This positively affects the demand for local anesthetics. The Global Local Anesthesia Drugs market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2029, growing at a CAGR of xx% during 2021-2029. This report focuses on Local Anesthesia Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Local Anesthesia Drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Asia and the Middle East Africa. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:

  • Mylan
  • Novartis
  • Fresenius Kabi
  • Aspen Pharmacare
  • Sagent Pharmaceutical
  • Pacira Pharmaceutical
  • Teva Pharmaceuticals
  • Pierrel group

Segment by Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

Segment by Type

  • Articaine
  • Bupivacaine
  • Lidocaine
  • Mepivacaine
  • Prilocaine

Segment by Application

  • Stomatology
  • Ophthalmology
  • Gynecology
  • Other

In October 2020,

Heron Therapeutics, B.V. received marketing authorization valid throughout the European Union for Zynrelef, which is a painkiller used in adults to reduce pain from small to medium-sized wounds after an operation. Zynrelef is a prolonged-release solution that is applied to the wound during surgery before the wound is closed. Prolonged-release means that the active substances are released slowly over several hours after application. It utilizes a novel, synergistic mechanism of action that combines bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. Bupivacaine is a local anesthetic that temporarily numbs the area to which it has been applied by blocking pain signals to the brain. Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), reduces pain and inflammation and strengthens the effect of bupivacaine. It has been shown to provide effective pain relief from small to medium-sized wounds after surgery. Its effect on reducing the need for opioid pain relief was considered modest but clinically significant. Heron's New Drug Submission (NDS) for HTX-011 for the management of postoperative pain was granted Priority Review status by Health Canada in October 2019 and accepted by Health Canada in November 2019. Heron is working to respond to a list of questions received from Health Canada in July 2020. Zynrelef is indicated for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. Heron is conducting The HOPE (Helping Opioid Prescription Elimination) Project evaluating HTX-011 as the foundation of non-opioid multimodal analgesia (MMA). *ZYNRELEF is the approved trade name for HTX-011 in the European Union.

In September 2020,

Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, announced the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for EXPAREL for postsurgical analgesia. The CHMP positive opinion was based on the results of four pivotal Phase 3 studies that demonstrated improvements in pain reduction and opioid use. The studies included Lower Extremity Nerve Block Study, Upper Extremity Nerve Block Study, Hard Tissue Infiltration Study, and Soft Tissue Infiltration Study EXPAREL is indicated in the United States for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Since its launch, EXPAREL has been used in over seven million patients.

Key Insights Covered: Global Postoperative Pain Therapeutics Service Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Postoperative Pain Therapeutics Service industry. 2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Postoperative Pain Therapeutics Service industry. 3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Postoperative Pain Therapeutics Service industry. 4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Postoperative Pain Therapeutics Service industry. 5. Global market size (sales, revenue) forecast by regions and countries from 2020 to 2029 of Postoperative Pain Therapeutics Service industry.

Research Methodology: Global Postoperative Pain Therapeutics Service Market

  • Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  • Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  • Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other

Table of Contents

Executive Summary
1 Local Anesthesia Drugs Market Overview
    1.1 Product Overview and Scope of Local Anesthesia Drugs
    1.2 Local Anesthesia Drugs Segment by Type
        1.2.1 Global Local Anesthesia Drugs Production Growth Rate Comparison by Type (2014-2025)
        1.2.2 Articaine
        1.2.3 Bupivacaine
        1.2.4 Lidocaine
        1.2.5 Mepivacaine
        1.2.6 Prilocaine
    1.3 Local Anesthesia Drugs Segment by Application
        1.3.1 Local Anesthesia Drugs Consumption Comparison by Application (2014-2025)
        1.3.2 Stomatology
        1.3.3 Ophthalmology
        1.3.4 Gynecology
        1.3.5 Other
    1.4 Global Local Anesthesia Drugs Market by Region
        1.4.1 Global Local Anesthesia Drugs Market Size Region
        1.4.2 North America Status and Prospect (2014-2025)
        1.4.3 Europe Status and Prospect (2014-2025)
        1.4.4 China Status and Prospect (2014-2025)
        1.4.5 Japan Status and Prospect (2014-2025)
    1.5 Global Local Anesthesia Drugs Market Size
        1.5.1 Global Local Anesthesia Drugs Revenue (2014-2025)
        1.5.2 Global Local Anesthesia Drugs Production (2014-2025)

2 Global Local Anesthesia Drugs Market Competition by Manufacturers
    2.1 Global Local Anesthesia Drugs Production Market Share by Manufacturers (2014-2019)
    2.2 Global Local Anesthesia Drugs Revenue Share by Manufacturers (2014-2019)
    2.3 Global Local Anesthesia Drugs Average Price by Manufacturers (2014-2019)
    2.4 Manufacturers Local Anesthesia Drugs Production Sites, Area Served, Product Types
    2.5 Local Anesthesia Drugs Market Competitive Situation and Trends
        2.5.1 Local Anesthesia Drugs Market Concentration Rate
        2.5.2 Local Anesthesia Drugs Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Local Anesthesia Drugs Production Market Share by Regions
    3.1 Global Local Anesthesia Drugs Production Market Share by Regions
    3.2 Global Local Anesthesia Drugs Revenue Market Share by Regions (2014-2019)
    3.3 Global Local Anesthesia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
    3.4 North ...
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form